argenx is running clinical trials of efgartigimod, an investigational FcRn antagonist

Our Commitment to Patients

Each day at argenx, we are motivated to pursue a better tomorrow alongside patients. We aim to do this through partnership because we know that "together we are better". As your ally, we pioneer innovations to advance the understanding of rare diseases; we want to deliver immunology treatments to patients worldwide.

We listen to patients, supporters and advocacy communities; we hear your stories and share your determination.

We integrate your aspirations into how we innovate, how we conduct research and design trials, and how we can support you in the daily struggles you face living with a rare disease.

There is a common purpose across argenx that is driven by your resilience and we welcome this opportunity to be with you on this journey.

Clinical trials

argenx is running clinical trials of efgartigimod, in development for a range of severe autoimmune diseases. For more info on clinical trials with efgartigimod, please click the link below.

Patient Access

argenx is committed to improving the lives of people suffering from severe autoimmune diseases and cancer. We aim to do this in partnership; by listening to patients, supporters and advocacy communities and hearing your stories. It is your words and your resilience that motivate us to advance the understanding of rare disease and work to deliver new treatments to as many patients as possible.

While we believe participation in a clinical trial is the most appropriate way to access investigational therapies, we understand that this is not possible for all patients. In these circumstances, argenx may consider making investigational therapies available outside of a clinical trial. This is typically done through an expanded access program. Today, argenx does not have an expanded access program available; however, this is something we continue to reassess.

Information about argenx clinical trials can be found here or on clinicaltrials.gov. Specific inquiries about policy on expanded access to argenx medicines may be made to earlyaccess@argenx.com.